Mr. Yousef Kamhiyah reports

GLOBAL HEMP GROUP ANNOUNCES APPOINTMENT OF YOUSEF KAMHIYAH AS CHIEF FINANCIAL OFFICER

Global Hemp Group Inc. has appointed Yousef Kamhiyah, CPA, CBV, as chief financial officer of the company.

Mr. Kamhiyah is a chartered professional accountant with a complementary Chartered Business Valuations licence. He brings over 15 years of extensive Canadian experience in accounting, business valuation, tax and business strategy. Demonstrating a highly technical proficiency with dual qualifications (CPA plus CBV), Mr. Kamhiyah has successfully valued over 100 companies spanning diverse industries. His leadership extends to the real estate sector, where he has overseen finance and accounting teams, ensuring meticulous accuracy, timely execution, and adherence to mandates.

Prior to assuming his role as Global Hemp's CFO, Mr. Kamhiyah established Accuvalue in 2019, his boutique CPA CBV firm based in Montreal, Canada. His strategic management approach has been instrumental in contributing to the success of various companies he has worked with in the past. Prior to the formation of his independent accounting company, Mr. Kamhiyah worked for a number of major accounting firms serving both public and private corporations in the areas of audit support, business and share valuations, and tax planning and compliance.

The company also announces the resignation of Stephen Barnhill Jr. as director of the company.

About Global Hemp Group Inc.

Global Hemp Group is a dynamic company currently focused on two key business segments -- industrial hemp and biopharma.

The industrial hemp division's primary focus lies in the environmental uses of hemp for construction and hemp for sustainable bio-energy sources, both contributing to a carbon-negative footprint. The company's R&D (research and development) team is engaged in developing intellectual property that can be patented and implemented within the company's projects and beyond. Prof. Victor M. Castano, PhD, a distinguished figure in applied science and nanotechnology, leads the R&D division for the organization. The health and wellness division is focused on the acquisition of exclusive patents and IP through licensing agreements. The company acquired exclusive the rights to key patents and IP of Apollon Formularies PLC, a United Kingdom-based international pharmaceutical company whose formulations and patents specialize in developing cancer treatments from natural biologics, including cannabinoids and functional mushrooms. More recently, the company has signed a letter of intent with B-Organic R&D Corp. relating to the use of its bioactive lipid agents (BLA) technology with cannabinoids, terpenes, flavonoids and mushroom extracts. BLA enhances the solubility and bioavailability of various "poorly soluble pharma ingredients."

These strategic alliances form the basis for the commercialization of promising independently preclinically tested formulations, underscoring the company's commitment to cutting-edge innovation in the commercial biopharma sector.

We seek Safe Harbor.